In the metastatic setting of CRC, ctDNA has been proven to sufficiently monitor the molecular clones that emerge during the course of treatment, especially in the RAS, BRAF, and EGFR status assessment, to consider the re-challenge with anti-EGFR treatment [74,75]. The gene discussed is EGFR; the disease is colorectal carcinoma.